A carregar...
Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
T-cell-based therapies have emerged as one of the most clinically effective ways to target solid and non-solid tumors. HER2 is responsible for the oncogenesis and treatment resistance of several human solid tumors. As a member of the HER family of tyrosine kinase receptors, its over-activity confers...
Na minha lista:
Publicado no: | Oncoimmunology |
---|---|
Main Authors: | , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Taylor & Francis
2017
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5384386/ https://ncbi.nlm.nih.gov/pubmed/28405494 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1267891 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|